In recent years, we have witnessed an explosion
of the information derived from genetics and biology
that has paved the way for better understanding of
physiology and pathology for a number of diseases. The area of
dyslipidemias is not an exception: with the advent of new
technologies for studies of the genetic code, the knowledge of human
genetics of lipoproteins has improved tremendously. The application of
this knowledge, paralleled by the understanding of the metabolic bases
for the genetic forms of dyslipidemias, has set the stage for the
identification of possible targets for pharmacological intervention and
for the development of new types of drugs. This meeting will address
these new frontiers as well as how this new knowledge affects our
clinical approach to the control of dyslipidemias and ultimately of
cardiovascular disease. Top scientists from the field will
address these issues with a series of lectures that will
benefit not only physicians, but also professionals in
pharmacology, genetics or biology with an
interest in this area.